Compare CHWY & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHWY | PCVX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.0B |
| IPO Year | 2019 | 2020 |
| Metric | CHWY | PCVX |
|---|---|---|
| Price | $26.00 | $59.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 4 |
| Target Price | $43.52 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 7.2M | 1.1M |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $12,601,500,000.00 | N/A |
| Revenue This Year | $10.70 | N/A |
| Revenue Next Year | $7.84 | N/A |
| P/E Ratio | $49.56 | ★ N/A |
| Revenue Growth | ★ 6.24 | N/A |
| 52 Week Low | $22.74 | $28.09 |
| 52 Week High | $48.62 | $65.00 |
| Indicator | CHWY | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 49.66 |
| Support Level | $24.75 | $52.04 |
| Resistance Level | $27.77 | $64.16 |
| Average True Range (ATR) | 1.15 | 2.20 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 27.67 | 17.50 |
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.